<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> is the second commonest form of <z:hpo ids='HP_0000726'>dementia</z:hpo>, and vascular factors contribute to the development of <z:hpo ids='HP_0000726'>dementia</z:hpo> in many patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Galantamine amplifies the <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> response by inhibiting acetylcholinesterase and modulating nicotinic receptors </plain></SENT>
<SENT sid="2" pm="."><plain>It has shown broad, sustained benefits in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the effects of galantamine in patients with a diagnosis of probable vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> or <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> combined with cerebrovascular disease </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Eligible patients were randomly assigned galantamine 24 mg/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial </plain></SENT>
<SENT sid="5" pm="."><plain>Primary endpoints were cognition (<z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input [CIBIC-plus]) </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary endpoints included assessments of activities of daily living and behavioural symptoms </plain></SENT>
<SENT sid="7" pm="."><plain>Patients were monitored for adverse events </plain></SENT>
<SENT sid="8" pm="."><plain>Analyses were on the basis of observed case or last observation carried forward </plain></SENT>
<SENT sid="9" pm="."><plain>FINDINGS: Galantamine showed greater efficacy than placebo on ADAS-cog (galantamine change -1.7 [SE 0.4] vs placebo 1.0 [0.5]; treatment effect 2.7 points; p&lt;0.0001) and CIBIC-plus (213 [74%] vs 95 [59%] patients remained stable or improved, p=0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>Activities of daily living and behavioural symptoms were also significantly improved compared with placebo (p=0.002 and p=0.016, respectively) </plain></SENT>
<SENT sid="11" pm="."><plain>Galantamine was well tolerated </plain></SENT>
<SENT sid="12" pm="."><plain>INTERPRETATION: Galantamine showed a therapeutic effect on <z:hpo ids='HP_0000001'>all</z:hpo> key areas of cognitive and non-cognitive abilities in this group of <z:hpo ids='HP_0000726'>dementia</z:hpo> patients </plain></SENT>
</text></document>